Metabolic gene, enzyme, and flux targets for cancer therapy

US10064885B2 · kind B2 · utility

Assignees

• Massachusetts Institute of Technology · US
• The General Hospital Corporation · US

Inventors

• Gregory Stephanopoulos · Pasadena, US
• Christian M. Metallo · San Diego, US
• Joanne K. Kelleher · Cambridge, US
• Othon Iliopoulos · Cambridge, US
• Paulo Alexandre da Costa Gameiro Guerreiro · Cambridge, US

Key dates

• Filing date: Jul 8, 2011
• Grant date: Sep 4, 2018
• Expiry date: Mar 3, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2310/531
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A novel pathway in cancer cell metabolism is identified. Targeting of any gene, protein, or enzyme that modulates activity or flux through this pathway, including, but not limited to IDH1, isocitrate dehydrogenase 2 (IDH2), aconitase 1 (ACO1), aconitase 2 (ACO2), glutaminase (GLS), glutamate dehydrogenase (GDH) and transaminase, provides effective means of inhibiting tumor growth.